Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease DOI Creative Commons

Tatjána Ábel,

Béla Benczúr, Éva Csajbókné Csobod

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 23, 2024

Previously published studies have shown that women with type 2 diabetes a higher risk of atherosclerotic cardiovascular disease than men diabetes. The exact reason for this is not yet known. association between metabolic dysfunction-associated steatotic liver and appears to be bidirectional, meaning the onset one may increase progression other. Dyslipidemia common in both diseases. Our aim was therefore investigate whether there sex difference pathogenesis management dyslipidemia patients dysfunction. While majority date found no statin treatment, some reduced effectiveness compared men. Statin treatment under-prescribed diabetics disease. No differences were ezetimibe treatment. However, best our knowledge, such study fibrate Conflicting results on efficacy newer cholesterol-lowering PCSK9 inhibitors been reported Results from two real-world suggest up-titration dose improves women. Bempedoic acid has effective safe more lipid lowering men, based phase 3 date. Further research needed clarify plays role ASCVD

Language: Английский

Editorial: Has MetALD met the presumption? DOI
Chee‐Kiat Tan

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 97 - 98

Published: May 17, 2024

LINKED CONTENT This article is linked to Tamaki et al papers. To view these articles, visit https://doi.org/10.1111/apt.18015 and https://doi.org/10.1111/apt.18047

Language: Английский

Citations

1
Distribution of Fibrosis‐4 index and vibration‐controlled transient elastography‐derived liver stiffness measurement for patients with metabolic dysfunction‐associated steatotic liver disease in health check‐up DOI

Yuji Ogawa,

Wataru Tomeno,

Yasushi Imamura

et al.

Hepatology Research, Journal Year: 2024, Volume and Issue: 55(2), P. 191 - 199

Published: Oct. 4, 2024

Abstract Aims The multisociety consensus nomenclature has introduced steatotic liver disease (SLD) with diverse subclassifications, which are metabolic dysfunction‐associated (MASLD), dysfunction and alcohol‐associated (MetALD), (ALD), specific etiology, cryptogenic. We investigated their prevalence, as per the new definition, in individuals undergoing health check‐ups. Additionally, we analyzed distribution of Fibrosis‐4 (FIB‐4) index vibration‐controlled transient elastography (VCTE)‐derived stiffness measurement (LSM) for MASLD. Methods In this cross‐sectional study, 6530 subjects a check‐up Japan were included. Conventional B‐mode ultrasound was carried out on all subjects, those MASLD underwent VCTE. Results prevalence SLD 39.5%, comprising 28.7%, MetALD 8.6%, ALD 1.2%, etiology 0.3%, cryptogenic 0.7%. Subjects VCTE‐derived LSM ≥8 kPa constituted 2.1% FIB‐4 ≥1.3 showed that sensitivity, specificity, positive predictive value (PPV), negative diagnosing 60.6%, 77.0%, 5.3%, 98.9%, respectively. referral rate to specialists 23.8% using ≥1.30. “FIB‐4 <65 years ≥2.0 ≥65 years” higher PPV (6.7%) lower (17.1%) compared ≥1.3, but sensitivity (54.5%) did not show adequate diagnostic capability noninvasive test kPa. Conclusions Acknowledging selection bias hepatology centers, undertook prospective study. Although proves be convenient marker, it might perform well primary screening tool fibrosis general population (UMIN Clinical Trials Registry No. UMIN000035188).

Language: Английский

Citations

1
Prevalence, characteristics and outcomes of patients with metabolic and alcohol related/associated liver disease: a systematic review and meta-analysis DOI
Maria Tampaki, Emmanuel Tsochatzis, Vasileios Lekakis

et al.

Metabolism, Journal Year: 2024, Volume and Issue: 163, P. 156101 - 156101

Published: Dec. 10, 2024

Language: Английский

Citations

1
Editorial: Has MetALD met the presumption? Authors' reply DOI
Nobuharu Tamaki, Takefumi Kimura,

Shun‐ichi Wakabayashi

et al.

Alimentary Pharmacology & Therapeutics, Journal Year: 2024, Volume and Issue: 60(1), P. 99 - 100

Published: May 17, 2024

LINKED CONTENT This article is linked to Tamaki et al papers. To view these articles, visit https://doi.org/10.1111/apt.18015 and https://doi.org/10.1111/apt.18034

Language: Английский

Citations

0
Sex differences in pathogenesis and treatment of dyslipidemia in patients with type 2 diabetes and steatotic liver disease DOI Creative Commons

Tatjána Ábel,

Béla Benczúr, Éva Csajbókné Csobod

et al.

Frontiers in Medicine, Journal Year: 2024, Volume and Issue: 11

Published: Sept. 23, 2024

Previously published studies have shown that women with type 2 diabetes a higher risk of atherosclerotic cardiovascular disease than men diabetes. The exact reason for this is not yet known. association between metabolic dysfunction-associated steatotic liver and appears to be bidirectional, meaning the onset one may increase progression other. Dyslipidemia common in both diseases. Our aim was therefore investigate whether there sex difference pathogenesis management dyslipidemia patients dysfunction. While majority date found no statin treatment, some reduced effectiveness compared men. Statin treatment under-prescribed diabetics disease. No differences were ezetimibe treatment. However, best our knowledge, such study fibrate Conflicting results on efficacy newer cholesterol-lowering PCSK9 inhibitors been reported Results from two real-world suggest up-titration dose improves women. Bempedoic acid has effective safe more lipid lowering men, based phase 3 date. Further research needed clarify plays role ASCVD

Language: Английский

Citations

0